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The human papillomavirus type 16 encodes two principal oncoproteins, E6 and E7. The E7 protein has been shown to
deregulate the cell cycle through interactions with a variety of proteins involved in cell cycle control and transcriptional
regulation. These activities result in E7 being able to cooperate with activated oncogenes in the transformation of primary
rodent cells, and with the viral E6 protein during human keratinocyte immortalization. Although a large number of activities
have been ascribed to the E7 protein, little is known about its regulation during the cell cycle. We have performed a series
of studies to investigate potential changes in E7 phosphorylation during the cell cycle and we show that E7 is indeed
differentially phosphorylated. Casein kinase II is the principal kinase during the early part of the cell cycle, but this activity
decreases rapidly as cells progress toward S phase. In addition, E7 is transiently phosphorylated at Ser71 in S phase by
another, as yet unknown, kinase. These results demonstrate differential regulation of the E7 protein during the cell cycle that
most likely represents a means of providing specificity to E7’s activities. © 2000 Academic Press
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Human papillomaviruses (HPVs) are the causative
agents of a number of human cancers, in particular
cervical cancer, in which HPV types 16 and 18 are pre-
dominately found (zur Hausen and Schneider, 1987).
These viruses encode two major oncoproteins, E6 and
E7. Both interfere with key elements in the cell cycle
control machinery and, as a result, induce cell cycle
progression in normally quiescent cells. While a major
role of E6 appears to be to overcome host-induced
apoptosis (Pan and Griep, 1995; Thomas and Banks,
1998), the E7 protein is largely responsible for induction
of the host DNA replication machinery (Bandara et al.,
1991; Phelps et al., 1991). HPV-16 E7 has been reported
to interact with a large number of cellular target proteins
and displays a large number of different phenotypic ef-
fects (Dyson et al., 1989; Davies et al., 1993; Tommasino
et al., 1993; Antinore et al., 1996; Massimi et al., 1996;
Zwerschke et al., 1999); however, a number of major
questions remain. It is presently unclear what provides
specificity to these different E7 interactions, since it is
unlikely that all could be carried out simultaneously. In
addition, there is no information as to whether E7 itself
might also be regulated during the cell cycle.
Phosphorylation represents a common means by
which proteins can be differentially regulated. Previous
studies have shown that E7 is phosphorylated by casein
kinase II (CKII) and that mutations which block this ac-
tivity reduce E7’s transforming ability (Barbosa et al.,1 To whom correspondence and reprint requests should be addressed.
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3881990; Storey et al., 1990; Firzlaff et al., 1991), suggesting
that phosphorylation by CKII is a significant factor in
regulating the function of E7. Another report also sug-
gested that E7 could be phosphorylated at additional
sites within the protein (Storey et al., 1990), but no further
studies on this have been reported. A number of studies
have also shown that CKII activity varies during the cell
cycle (Russo et al., 1992; Pepperkok et al., 1994; Lorenz
et al., 1999). We were therefore interested in investigating
the phosphorylation status of the HPV-16 E7 protein as
cells enter the cell cycle, since this is the point at which
E7 would appear to exert most of its activities. We show
that E7 is highly phosphorylated by CKII during the G1
phase of the cell cycle, but this rapidly decreases as
cells enter S phase. However, at this time E7 becomes
phosphorylated on serine 71 by another, as yet unknown,
kinase. These results demonstrate that E7 is indeed
differentially phosphorylated during the cell cycle.
RESULTS AND DISCUSSION
To investigate the phosphorylation of E7 during the
cell cycle we first performed an in vivo labeling experi-
ment and immunoprecipitation analysis at different
points during the cell cycle. Transformed baby rat kidney
epithelial cells expressing HPV-16 E7 and EJ-ras were
growth-arrested in low serum for 48 h and then induced
to reenter the cell cycle by addition of 10% fetal calf
serum. At the same time the cells were labeled for 1 h
with [32P]-orthophosphate at different times post addition
of serum. Cell extracts were then made and the radiola-
beled E7 was detected by immunoprecipitation. The re-
sults are shown in Fig. 1. The upper part of the figure
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389DIFFERENTIAL PHOSPHORYLATION OF HPV-16-E7 ONCOPROTEINshows the level of bromodeoxyuridine (BUDR) incorpo-
ration. This shows first that the cells are indeed growth
arrested and, second that the cells are in maximal S
phase approximately 6 h post addition of serum. As can
be seen in Fig. 1B there are two different patterns of E7
phosphorylation. At time zero HPV-16 E7 is heavily phos-
phorylated but as the cells enter the cycle this rapidly
decreases. However, at time points close to maximal S
phase there is again an increase in the levels of E7
phosphorylation. The lower panel shows the parallel
Western blot which demonstrates that there are constant
levels of E7 protein during the course of the experiment.
These results show that E7 is differentially phosphory-
lated during the cell cycle.
Since HPV-16 E7 has previously been shown to be phos-
phorylated by CKII (Barbosa et al., 1990), we next investi-
FIG. 1. Differential phosphorylation of HPV-16 E7 during the cell
cycle. Transformed BRK cells were growth arrested in 0.2% fetal calf
serum for 48 h and subsequently induced with 10% fetal calf serum. (A)
The percentage of cells incorporating BUDR during 1-h pulses follow-
ing the addition of calf serum. (B) Immunoprecipitation of HPV-16 E7
protein from extracts of the cells radiolabeled with [32P]orthophosphate.
(C) Parallel Western blot analysis of E7 protein expression during the
period of the time course. Positive control (1) extracts from CaSKI cells
and negative control (2) extracts from C33I cells.gated whether these changes in the phosphorylation status
of E7 were due to changes in CKII activity. To do this,wild-type E7 and an E7 mutant (31Ser32Ser/31Arg32Pro)
that is defective for CKII phosphorylation (Barbosa et al.,
1990) were produced as GST fusion proteins and purified.
Extracts were made form the BRK cells that had been
growth arrested and serum induced, as described above,
and in vitro kinase assays were then performed on the two
GST fusion proteins. The results obtained are shown in Fig.
2 and it is clear that the wild-type E7 protein is phosphor-
ylated in a manner very similar to that seen in vivo. The
protein is heavily phosphorylated by extracts from the
growth-arrested cells, and this kinase activity subsequently
decreases as the cells enter the cycle. However, a marked
increase in E7 phosphorylation is obtained with extracts
from cells approaching maximal S phase. Strikingly, the
CKII defective mutant of E7 is not phosphorylated with
extracts from the growth-arrested cells, but once the cells
reach maximal S phase a very similar pattern of phosphor-
ylation is seen to that obtained with the wild-type protein.
These results demonstrate that CKII specifically phosphor-
ylates E7 early in the cell cycle, but as cells enter S phase
this activity dramatically decreases. In addition, E7 is
heavily phosphorylated later in S phase by another, as yet
unidentified, kinase.
In order to verify that E7 defective for CKII phosphor-
ylation is indeed phosphorylated in vivo, immunoprecipi-
tation analysis was performed on BRK cells transformed
with either wild-type E7 or two mutants of E7 defective
for CKII phosphorylation, p31/32ArgPro and p31/32As-
pAsp. Cells were radiolabeled in the presence of
[32P]orthophosphate and after 1 h cells were harvested
nd immunoprecipitations were performed as described
reviously (Banks and Crawford, 1988). The results ob-
ained are shown in Fig. 3A. As can be seen, both the
ild-type and the mutant E7 proteins are phosphory-
ated, although p31/32ArgPro is much weaker than the
ild-type or the p31/32AspAsp mutant. Western blot
nalysis of the E7 protein in the different cell lines is
hown in Fig. 3B and it is clear that the p31/32AspAsp
utant is more highly expressed than either wild-type E7
r the p31/32ArgPro mutant. It is clear from this analysis
hat p31/32AspAsp is phosphorylated, confirming the
pecificity of the in vitro kinase assays, and demon-
trates that E7 is indeed phosphorylated at residues
ther than at the CKII recognition site.
Since the above assays were performed in BRK cells
ransformed with E7 and EJ-ras, we next investigated the
attern of E7 phosphorylation in keratinocytes lacking
PV DNA sequences. To do this, in vitro kinase assays
were performed on GST-E7 as described for Fig. 2, using
extracts derived from HaCat cells at different phases of
the cell cycle. The results obtained are shown in Fig. 4A
and again demonstrate high levels of E7 phosphorylation
in growth-arrested cells, followed by a decrease as cells
are stimulated to enter the cell cycle. This is then fol-
lowed by a marked increase in phosphorylation as the
cells enter S phase. Figure 4B shows the cell cycle
p
y
(
ndard
390 MASSIMI AND BANKSanalysis confirming the entry into S phase 4 h post
addition of serum. These results demonstrate that E7 is
also differentially phosphorylated using extracts of ker-
atinocytes at different phases of the cell cycle.
FIG. 2. In vitro phosphorylation of GST.16E7 and GST.p31/32 fusion p
obtained at different times post addition of serum. Purified E7 fusion p
the presence of radiolabeled [32P]gATP. Following extensive washing t
Phosphorylated proteins were quantitated by Phosphor Imager analysis
phosphorylation assays using different cell extracts together with the sta
was done to verify S phase entry at 4 h post addition of serum.Previous studies had indicated a weak phosphorylation
of E7 within the carboxy terminus of the protein at Ser71
r
o(Storey et al., 1990). In order to investigate the role of this
otential phosphorylation site in the differential phosphor-
lation of E7, we expressed the Ser71/Gly71 E7 mutant
Storey et al., 1990) as a GST fusion protein and then
. BRK cells were growth arrested as for Fig. 1 and cell extracts were
were then subjected to in vitro kinase assays with the cell extracts in
olabeled proteins were analysed by SDS–PAGE and autoradiography.
Wild-type HPV-16 E7 together with the mean values from four different
deviation. (Bottom) The p31/32 mutant. In all cases BUDR incorporationroteins
roteins
he radi
. (Top)epeated the in vitro phosphorylation analysis. The results
btained are shown in Fig. 5. As can be seen, the wild-type
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391DIFFERENTIAL PHOSPHORYLATION OF HPV-16-E7 ONCOPROTEINE7 is again phosphorylated in a manner similar to that seen
in Fig. 2. Interestingly, the Ser71 mutant is phosphorylated
by extracts from the growth-arrested cells, which is consis-
tent with this phosphorylation being performed by CKII.
However, no phosphorylation of the Ser71 mutant is seen
later in the cell cycle, suggesting that phosphorylation of E7
during S phase occurs at Ser71.
Previous studies showing that HPV-16 E7 was phos-
phorylated gave no information about how this might
change during the cell cycle (Barbosa et al., 1990;
Storey et al., 1990; Massimi et al., 1996). However, E7
hosphorylation is an important modification since
utants of E7 which are defective for CKII phosphor-
lation are also reduced in their ability to transform
ells (Barbosa et al., 1990; Storey et al., 1990; Firzlaff et
l., 1991). In this study we have shown conclusively
hat CKII activity on E7 changes dramatically as cells
rogress through the cell cycle. Since the cells growth
rrested by serum starvation enter S phase quite rap-
dly upon serum addition, the serum-starved BRK cells
re most likely arrested in mid to late G1. Clearly,
uring this phase of the cell cycle there is very heavy
KII phosphorylation of E7. This is consistent with the
otion that CKII phosphorylation affects E7’s ability to
nduce cell transformation and also contributes to its
bility to induce DNA synthesis (Banks et al., 1990a),
he latter activity of E7 being at its peak during mid to
ate G1. However, once cells enter S phase the CKII
hosphorylation of E7 decreases dramatically and this
s consistent with the role of E7 changing at this point
n the cycle. Interestingly, as cells reach maximal S
hase E7 is phosphorylated by another unknown ki-
ase at Ser71. At present it is not clear what effect this
hosphorylation event has upon E7 function, since
revious studies had indicated that this mutant E7
ould transform BRK cells with wild-type efficiency
Storey et al., 1990). It should also be borne in mind
FIG. 3. (A) In vivo phosphorylation of HPV-16 E7 mutant proteins. BR
either p31/32 Arg/Pro (31/32) or p31/32 Asp/Asp (Asp. mut.) mutants plu
harvested and E7 was immunoprecipitated with an anti-E7 polyclonal a
The position of E7 is indicated by an arrow. (B) Western blot analysis of
E7 (E7), p31/32Asp/Asp (Asp), p31/32Arg/Pro (31/32), and EJ-ras alonehat these assays are based on cells that enter the cell
ycle from a serum-arrested state and it will now be ofnterest to analyze E7 phosphorylation status in nor-
al cycling cells.
HPV-16 E7 is a multifunctional protein with many
ifferent cellular targets and activities. A key question
oncerning the activities of such small and low-abun-
ance DNA tumor virus proteins is how they can pos-
ibly perform so many apparently divergent tasks. The
ata presented here begin to provide some of the
nswers to this question. Clearly differential phos-
horylation of E7 is likely to alter its function during
ifferent phases of the cell cycle. This implies that E7
as defined activities at specific points within the cell
ycle and that phosphorylation of the viral protein
ives specificity to these functions. Studies are now in
rogress to identify the Ser71 kinase and to assess the
nteractions of E7 with its different target proteins
uring the cell cycle.
MATERIALS AND METHODS
ells
Transformed BRK cells expressing HPV-16 E7 and EJ-
as were obtained as described previously (Massimi et
l., 1997). BRK cells and HaCat cells were grown in
MEM supplemented with 10% fetal calf serum.
n vivo labeling and immunoprecipitation
BRK cells were placed in 0.2% fetal calf serum for
8 h and then placed in phosphate-free medium for a
urther 2 h. After this time 1 mCi [32P]orthophosphate
was added to the time zero cells for 1 h. The remaining
cells were induced with 10% fetal calf serum and
labeled with 1 mCi [32P]orthophosphate for 1 h at
different times after serum addition. Cells were har-
vested at 2-h intervals, extracted with E1a buffer as
described previously (Banks and Crawford, 1988), and
immunoprecipitated with a rabbit polyclonal anti-E7
transformed with wild-type E7 plus EJ-ras (E7), EJ-ras (ras) alone, and
s were radiolabeled with [32P]orthophosphate. After 1 h the cells were
. Precipitates were then analysed by SDS–PAGE and autoradiography.
tein expression in the transformed BRK cell lines expressing wild-typeK cells
s EJ-ra
ntibodyantibody. Immunoprecipitates were run on SDS–PAGE
and analyzed by autoradiography.
nt 2-h
y entry
392 MASSIMI AND BANKSCell cycle analysis
Cells were plated on coverslips and placed in 0.2%
serum for 48 h. Medium was then added containing
10% fetal calf serum, and 20 mM BUDR (Sigma) was
added for periods of 1 h at different time points post
addition of serum. Immunofluorescence was then per-
formed using anti-BUDR antibody (Sigma) and cells
were counterstained with Hoechst solution. The per-
centage of BUDR-positive cells versus the number of
total cells was then calculated for each time point.
FIG. 4. In vitro phosphorylation of the GST.16E7 fusion protein with Ha
obtained at different times post addition of serum. The purified E7 fusi
in the presence of radiolabeled gATP. Following extensive washing the
FACS analysis of growth-arrested HaCat cells (time 0) and at subseque
obtained between 4 and 6 h post addition of serum. This is followed bAlternatively, cells were harvested at different times
post addition of serum and DNA content was as-sessed by propidium iodide staining and FACS analy-
sis as described previously (Banks et al., 1990b).
In vitro kinase assays
BRK cells were placed in 0.2% fetal calf serum for
48 h, after which time 10% fetal calf serum was added
back to the cells and cells were extracted in lysis
buffer (250 mM NaCl, 0.15% NP-40, 50 mM HEPES pH
7, 1% aprotinin, 100 mM TLCK, 200 mM TPCK, 50 mM
NaF, 4 mM Na3 VO4, 100 mM K2 HPO4) at different time
ll extracts. (A) HaCat cells were growth arrested and cell extracts were
ein was then subjected to in vitro kinase assays with the cell extracts
beled proteins were analysed by SDS–PAGE and autoradiography. (B)
intervals post addition of serum. As can be seen, maximal S phase is
into G2M and G1 by 8 h.Cat ce
on prot
radiolapoints post addition of serum. Equal amounts of puri-
fied GST fusion proteins were then incubated with the
w
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393DIFFERENTIAL PHOSPHORYLATION OF HPV-16-E7 ONCOPROTEINcell extracts for 20 min at 30°C in phosphorylation
buffer (20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.3 mM
aprotinin, 1 mM/Pepstatin) containing 56 nM [32P]ATP
(Amersham) and 10 mM ATP. After being extensively
ashed, the phosphorylated proteins were monitored
y SDS–PAGE and autoradiography. The level of phos-
horylation was quantitated using a Packard Instant
hosphor Imager.
estern blotting
Extracts were prepared from serum-stimulated BRK
ells at different time points post addition of serum, as
escribed previously (Banks and Crawford, 1988). Pro-
eins were then run on SDS–PAGE and transferred to
itrocellulose and E7 was detected using a rabbit anti-E7
olyclonal antibody and ECL detection according to the
anufacturer’s instructions (Amersham).
ST fusion proteins
FIG. 5. In vitro phosphorylation of GST.16E7 and GST.Ser71 fusion p
obtained at different times post addition of serum. Purified E7 fusion p
the presence of radiolabeled [32P]gATP. Following extensive washing t
Phosphorylated proteins were quantitated by Phosphor Imager analys
equal loading of the fusion proteins. (Top) Wild-type HPV-16 E7 and (bThese were induced and purified as described previ-
usly (Massimi et al., 1996).
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